Cargando…
High thioredoxin-1 levels in rheumatoid arthritis patients diminish binding and signalling of the monoclonal antibody Tregalizumab
The humanized non-depleting anti-CD4 monoclonal antibody Tregalizumab (BT-061) is able to selectively activate the suppressive function of regulatory T cells and has been investigated up to phase IIb in clinical trials in patients suffering from rheumatoid arthritis (RA). A pharmacokinetic–pharmacod...
Autores principales: | Heim, Katharina, Dälken, Benjamin, Faust, Stefanie, Rharbaoui, Faiza, Engling, Andre, Wallmeier, Holger, Dingermann, Theodor, Radeke, Heinfried H, Schüttrumpf, Jörg, Gutscher, Marcus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192061/ https://www.ncbi.nlm.nih.gov/pubmed/28090323 http://dx.doi.org/10.1038/cti.2016.69 |
Ejemplares similares
-
Tregalizumab – A Monoclonal Antibody to Target Regulatory T Cells
por: König, Martin, et al.
Publicado: (2016) -
A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway
por: Helling, Bianca, et al.
Publicado: (2015) -
The Functional Role of IgA in the IgM/IgA-Enriched Immunoglobulin Preparation Trimodulin
por: Bohländer, Fabian, et al.
Publicado: (2021) -
Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI
por: Bohländer, Fabian, et al.
Publicado: (2021) -
Grundlagen der Pharmakologie von Cannabinoiden
por: Dingermann, Theodor
Publicado: (2021)